MabCampath is used to treat patients with B-cell chronic lymphocytic leukaemia (B-CLL), a cancer of a type of white blood cell called B lymphocytes. MabCampath is used in patients for whom treatment combinations including fludarabine (another medicine used in leukaemia) are not appropriate. The medicine can only be obtained with a prescription.
- Medicine Name: Mabcampath
- Generic Name: Alemtuzumab
- Approval Date: 2001
- Company Name: Genzyme Corporation
- Available as (Form & Strength): 30 mg/1 mL single use vial